Navigation Links
Nanobiosym awarded $2 million DTRA contract
Date:9/26/2007

MEDFORD, Mass., September 26, 2007 Nanobiosym Inc., announced today that it has been awarded a highly competitive $2 million contract from the United States Defense Threat Reduction Agency (DTRA), a branch of the US Department of Defense. The winners of this award were selected after an intense competition among many of the nations leading US academic, government, and industrial labs.

Nanobiosym, and its commercial partner Nanobiosym Diagnostics, have been privately developing Gene-RADAR, a portable nanotechnology-enabled platform, that can rapidly and accurately detect genetic fingerprints from any biological organism. The companys vision is to give patients worldwide real-time access to their own diagnostic information via low-cost handheld devices. Nanobiosym Diagnostics also seeks to leverage its nanotechnology platform to enable portable real-time detection of food and air-borne pathogens, as well as water testing, animal and crop testing, and screening of blood and transplant organs.

We are delighted that DTRA has recognized our unique proprietary technological platform with this award, said Dr. Anita Goel, M.D., PhD., Chairman and CEO of Nanobiosym. This is our first defense contract and is a major step towards establishing the US government as one of our long-term customers. Nanobiosym has been previously recognized by several other prominent awards, including multiple rounds of funding from the Defense Advance Research Project Agency (DARPA), the Air Force Office of Scientific Research (AFOSR), and the U.S. Department of Energy (DOE). Nanobiosym shares DTRAs strategic mission to reduce the threat of biological warfare and bioterrorism and during the course of the DTRA contract plans to validate the use of Nanobiosyms proprietary technology platform for emerging biodefense applications. In the coming years, we envision a significant paradigm shift in healthcare where the ability to diagnose disease is taken out of a pathology lab and brought into doctors clinics, peoples homes, and even rural villages. said Dr. Goel. This is similar to the paradigm shift that occurred in the telecom industry when communications and computing devices became portable. Nanobiosym is also actively adapting its Gene-RADAR system to address unmet healthcare needs in the developing world, where the lack of basic infrastructure often precludes effective diagnostics.


'/>"/>

Contact: NBS Media & Public Relations
Info@nanobiosym.com
781-391-7979
Feinstein Kean Healthcare
Source:Eurekalert

Related biology news :

1. TGen awarded $7.1 million to accelerate brain disease research
2. A comprehensive response to HIV could prevent 10 million AIDS deaths in Africa by 2020
3. UCLA launches $20 million stem cell institute to investigate HIV, cancer and neurological disorders
4. Six million Africans face famine because of locusts, drought
5. Retrovirus struck ancestors of chimpanzees and gorillas millions of years ago, but did not affect ancestral humans
6. Evidence of 600-million-year old fungi-algae symbiosis discovered in marine fossils
7. $5.1 billion would save 6 million children
8. Health costs soar as 60 million Americans classed as obese
9. Malaria killing a million a year
10. $6.5 Million Grant for Microarray Center at Yale School of Medicine
11. MSU researchers receive $4 million grant to uncover gene functions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC , ... announced the opening of an IoT Center of Excellence ... and expand the development of embedded iris biometric applications. ... level of convenience and security with unmatched biometric accuracy, ... identity aside from DNA. EyeLock,s platform uses video technology ...
(Date:5/9/2016)... -- Elevay is currently known as the ... high net worth professionals seeking travel for work   ... there is still no substitute for a face-to-face meeting. ... deal with a firm handshake. This is why wealthy ... citizenship via investment programs like those offered by the ...
(Date:4/28/2016)... , April 28, 2016 Infosys ... (NYSE: INFY ), and Samsung SDS, a global ... that will provide end customers with a more secure, fast ...      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... but it also plays a fundamental part in enabling and ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. ... test has received AOAC Research Institute approval 061601. , “This is another AOAC-RI ... stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate ...
Breaking Biology Technology: